Cerevel Therapeutics is a clinical-stage biopharmaceutical company that combines a deep understanding of the biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) receptor pharmacology to discover and develop new therapies. The company was founded through a partnership with Pfizer and Bain Capital.
Cerevel Therapeutics is committed to unraveling the mysteries of the brain in treating neuroscience diseases. The company has a diversified pipeline that comprises five clinical-stage investigational therapies and several pre-clinical compounds with the potential to treat a wide range of neuroscience diseases that includes Parkinson’s, epilepsy, schizophrenia, and substance use disorder.
Cerevel Therapeutics is making its current research and development programs, and the company is exploring new modalities via internal research efforts, external collaborations, or potential acquisitions.
